For instance, Hu et al. engineered CAR-T cells with dual antigen targeting of CD19 and CD22, which could recognize the two tumor-associated antigens simultaneously and thus showed significant clinical therapeutic efficacy with low CD19− relapse rate [8]. This evidence concerns the gene CD19 and neoplasm.